Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Consensus Rating of “Moderate Buy” by Brokerages

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) has received a consensus rating of “Moderate Buy” from the five research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $8.75.

A number of equities research analysts recently issued reports on RANI shares. Weiss Ratings cut shares of Rani Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 17th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $5.00 price objective on shares of Rani Therapeutics in a research note on Wednesday, May 20th. Wall Street Zen raised shares of Rani Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, May 17th. Finally, Lake Street Capital initiated coverage on shares of Rani Therapeutics in a research note on Tuesday, April 14th. They issued a “buy” rating and a $9.00 target price for the company.

Insider Transactions at Rani Therapeutics

In other Rani Therapeutics news, CEO Talat Imran acquired 35,000 shares of the business’s stock in a transaction on Friday, July 17th. The stock was purchased at an average price of $0.72 per share, for a total transaction of $25,200.00. Following the transaction, the chief executive officer owned 469,736 shares in the company, valued at $338,209.92. This trade represents a 8.05% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 26.73% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in RANI. RA Capital Management L.P. bought a new position in shares of Rani Therapeutics in the fourth quarter worth about $11,475,000. AWM Investment Company Inc. acquired a new stake in shares of Rani Therapeutics in the fourth quarter valued at approximately $8,775,000. SymBiosis Capital Partners LLC bought a new position in Rani Therapeutics in the 4th quarter worth approximately $8,505,000. Armistice Capital LLC acquired a new position in Rani Therapeutics during the 2nd quarter worth $1,619,000. Finally, Siren L.L.C. bought a new position in Rani Therapeutics in the 4th quarter valued at $2,700,000. Institutional investors and hedge funds own 30.19% of the company’s stock.

Rani Therapeutics Stock Performance

Shares of Rani Therapeutics stock opened at $0.78 on Tuesday. The firm’s 50-day simple moving average is $0.77 and its 200-day simple moving average is $0.99. Rani Therapeutics has a twelve month low of $0.44 and a twelve month high of $3.87. The firm has a market cap of $96.24 million, a P/E ratio of -1.89 and a beta of 0.78.

Rani Therapeutics (NASDAQ:RANI) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.02. The business had revenue of $1.71 million during the quarter, compared to analyst estimates of $1.12 million. On average, equities analysts forecast that Rani Therapeutics will post -0.17 earnings per share for the current fiscal year.

Rani Therapeutics Company Profile

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.